Publication:
Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany

dc.contributor.authorKasper, Siegfried
dc.contributor.authorBonelli, Annalisa
dc.contributor.authorCattaneo, Agnese
dc.contributor.authorComandini, Alessandro
dc.contributor.authorDi Dato, Giorgio
dc.contributor.authorHeiman, Franca
dc.contributor.authorPegoraro, Valeria
dc.contributor.authorPalao, Diego
dc.contributor.authorRoca, Miquel
dc.contributor.authorVolz, Hans-Peter
dc.date.accessioned2024-09-18T06:45:04Z
dc.date.available2024-09-18T06:45:04Z
dc.date.issued2021-11-02
dc.description.abstractObjective: To identify sick leave days (SLD) predictors after starting antidepressant (AD) treatment in patients affected by major depressive disorder (MDD), managed by general practitioners, with a focus on different AD therapeutic approaches. Methods: Retrospective study on German IQVIA(R) Disease Analyser database. 19-64 year old MDD patients initiating AD treatment between July-2016 and June-2018 were grouped by therapeutic approach (AD monotherapy versus combination/switch/add-on). Data were analysed descriptively by AD therapeutic approach, while a zero-inflated Poisson (ZIP) multiple regression model was run to evaluate SLD predictors. Results: 8,891 patients met inclusion criteria (monotherapy: 66%; combination/switch/add-on: 34%). All covariates had an influence on SLD after AD treatment initiation. Focussing on variables that physicians may more easily intervene to improve outcomes, it was found that the expected SLD number of combination/switch/add-on patients was 1.6 times that of monotherapy patients, and the expected SLD number of patients diagnosed with MDD before the decision to start AD treatment was 1.2 times that of patients not diagnosed with MDD. Conclusions: A patient tailored approach in the selection of AD treatment at the time of MDD diagnosis may improve functional recovery and help to reduce the socio-economic burden of the disease.en
dc.description.sponsorshipThis study was funded by Angelini Pharma S.p.A. Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, and Giorgio Di Dato are employees of Angelini Pharma S.p.A. Franca Heiman and Valeria Pegoraro are employees of IQVIA. Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celgene GmbH, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sage, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd. and Takeda. Miquel Roca received research funds or grants from Angelini, Janssen, Lundbeck and Pfizer. Hans-Peter Volz received grants/research support, consulting fees and/or honoraria within the last three years from Lundbeck, Pfizer, Schwabe, Bayer, Janssen-Cilag, Neuraxpharm, Recordati, AstraZeneca, Gilead, Servier, Otsuka, Recordati. Diego Palao has received grants and also served as consultant or advisor for Angelini, Janssen, Lundbeck and Servier.es_ES
dc.format.number4es_ES
dc.format.page393-402es_ES
dc.format.volume25es_ES
dc.identifier.citationKasper S, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, et al. Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. Int J Psychiat Clin. 2021 Nov 2;25(4):393-402.en
dc.identifier.doi10.1080/13651501.2021.1972120
dc.identifier.e-issn1471-1788es_ES
dc.identifier.issn1365-1501
dc.identifier.journalInternational Journal of Psychiatry in Clinical Practicees_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19762
dc.identifier.pubmedID34543170es_ES
dc.identifier.puiL2013743782
dc.identifier.scopus2-s2.0-85115205163
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23349
dc.identifier.wos698226100001
dc.language.isoengen
dc.publisherTaylor & Francis
dc.relation.publisherversionhttps://dx.doi.org/10.1080/13651501.2021.1972120en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMajor depressive disorder
dc.subjectSick leave
dc.subjectAntidepressants
dc.subjectTherapeutic approach
dc.subjectReal world evidence
dc.subject.decsAntidepresivos*
dc.subject.decsTrastorno Depresivo Mayor*
dc.subject.decsHumanos*
dc.subject.decsPersona de Mediana Edad*
dc.subject.decsAdulto Joven*
dc.subject.decsAusencia por Enfermedad*
dc.subject.decsAlemania*
dc.subject.decsEstudios Retrospectivos*
dc.subject.decsAdulto*
dc.subject.decsMedicina General*
dc.subject.meshSick Leave*
dc.subject.meshGeneral Practice*
dc.subject.meshDepressive Disorder, Major*
dc.subject.meshYoung Adult*
dc.subject.meshAdult*
dc.subject.meshGermany*
dc.subject.meshAntidepressive Agents*
dc.subject.meshHumans*
dc.subject.meshMiddle Aged*
dc.subject.meshRetrospective Studies*
dc.titlePredictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germanyen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationaf7833ee-b4f1-4914-9339-d65cbe8472b9
relation.isPublisherOfPublication.latestForDiscoveryaf7833ee-b4f1-4914-9339-d65cbe8472b9

Files